Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2017

01-07-2017 | Endocrine Trials

The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial

Authors: Shabnam Salekzamani, Abolhassan Shakeri Bavil, Hossein Mehralizadeh, Mohammad Asghari Jafarabadi, Aymaral Ghezel, Bahram Pourghassem Gargari

Published in: Endocrine | Issue 1/2017

Login to get access

Abstract

Purpose

Metabolic syndrome may predispose to cardiovascular diseases. Since, in recent studies, vitamin D is advocated for cardioprotective roles, this study was designed to investigate the effects of vitamin D supplementation on proatherogenic inflammatory markers and common carotid intima media thickness in subjects with metabolic syndrome.

Methods

This randomized double blind clinical trial was conducted in Tabriz, Iran. Eligible subjects (n = 80) with metabolic syndrome were recruited thorough advertisement and randomized to receive either vitamin D (50,000 IU/week) or matching placebo for 16 weeks. Interlukin-6, high sensitivity C-reactive protein, vascular cell adhesion molecule-1, E-selectin, and common carotid intima media thickness were measured at the beginning and end of the study. The study was registered at http://​www.​irct.​ir (code: IRCT201409033140N14).

Results

Sixteen weeks supplementation with vitamin D increased median of serum 25-hydroxy vitamin D [25(OH)D] and mean calcium levels (p < 0.001) in the intervention group. There was also a significant difference in parathyroid hormone level at the end of the study (p < 0.001). Vitamin D treatment reduced IL-6 level after 16 weeks (p = 0.027). Compared to baseline, vascular cell adhesion molecule-1 and E-selectin levels decreased significantly in vitamin D treated subjects; however, there were no significant differences between two groups. No effect of vitamin D supplementation was observed in either common carotid intima media thickness or high sensitivity C-reactive protein concentrations at the end of the study (p > 0.05).

Conclusions

Vitamin D supplementation improved some proatherogenic inflammatory markers in subjects with metabolic syndrome. No changes of high sensitivity C-reactive protein and carotid intima media thickness were shown after 16 weeks.
Appendix
Available only for authorised users
Literature
1.
K. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C. Fruchart, W.P. James, C.M. Loria, S.C. Smith, Harmonizing the metabolic syndrome a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 120, 1640–1645 (2009)CrossRefPubMed
2.
E. Kaperonis, C. Liapis, J. Kakisis, D. Dimitroulis, V. Papavassiliou, Inflammation and atherosclerosis. Eur. J. Vasc. Endovasc. Surg. 31, 386–393 (2006)CrossRefPubMed
3.
E. Ingelsson, J. Hulthe, L. Lind, Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Eur. J. Clin. Invest. 38, 502–509 (2008)CrossRefPubMed
4.
H. Schuett, M. Luchtefeld, C. Grothusen, K. Grote, B. Schieffer, How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb. Haemost. 102, 215–222 (2009)CrossRefPubMed
5.
U.I. Christiana, A.E. Casimir, A.A. Nicholas, M.C. Christian, A.I. Obiefuna, Plasma levels of inflammatory cytokines in adult Nigerians with the metabolic syndrome. Niger. Med. J. 57, 64–68 (2016)CrossRefPubMed
6.
T.W. Weiss, H. Arnesen, I. Seljeflot, Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metabolism. 62, 1008–1013 (2013)CrossRefPubMed
7.
J.F. Polak, M.J. Pencina, K.M. Pencina, C.J. O’Donnell, P.A. Wolf, R.B. D’Agostino Sr, Carotid-wall intima–media thickness and cardiovascular events. New.Eng. J. Med. 365, 213–221 (2011)CrossRefPubMed
8.
P.J. Touboul, D.E. Grobbee, H. den Ruijter, Assessment of subclinical atherosclerosis by carotid intima media thickness: technical issues. Eur. J. Prev. Cardiol 19, 18–24 (2012)CrossRefPubMed
9.
A.G. Panayiotou, M. Griffin, P. Kouis, T. Tyllis, N. Georgiou, D. Bond, A.N. Nicolaides, Association between presence of the metabolic syndrome and its components with carotid intima-media thickness and carotid and femoral plaque area: a population study. Diabetol. Metab. Syndr 5, 44–53 (2013)CrossRefPubMed
10.
L.H. Li, X.Y. Yin, C.Y. Yao, C.X. Zhu, X.H. Wu, Serum 25-hydroxyvitamin D, parathyroid hormone, and their association with metabolic syndrome in Chinese. Endocrine. 44, 465–472 (2013)CrossRefPubMed
11.
C. Gagnon, Z.X. Lu, D.J. Magliano, D.W. Dunstan, J.E. Shaw, P.Z. Zimmet, K. Sikaris, P.R. Ebeling, R.M. Daly, Low Serum 25-Hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). J. Clin. Endocrinol. Metab. 97, 1953–1961 (2012)CrossRefPubMed
12.
G. Muscogiuri, V. Nuzzo, A. Gatti, A. Zuccoli, S. Savastano, C. Di Somma, R. Pivonello, F. Orio, A. Cola, Hypovitaminosis D: a novel risk factor for coronary heart disease in type 2 diabetes? Endocrine. 51, 268–273 (2016)CrossRefPubMed
13.
S.Y. Ju, H.S. Jeong, D.H. Kim, Blood vitamin D status and metabolic syndrome in the general adult population: a dose-response meta-analysis. J. Clin. Endocrinol. Metab. 17, 1053–1063 (2013)
14.
R. Bouillon, L. Verlinden, Does a better vitamin D status help to reduce cardiovascular risks and events. Endocrine. 47, 662–663 (2014)CrossRefPubMed
15.
A. Di Nisio, L.D. Toni, E. D’Addato, M.R. Pizzo, P. Sabatino, C. Foresta, 25-Hydroxy vitamin D insufficiency discriminates cardiovascular risk factors accumulation in peri-pubertal boys undergoing overweight screening. Endocrine. 53, 530–537 (2016)CrossRefPubMed
16.
G. Sarno, G. Daniele, G. Tirabassi, A.O. Chavez, O.O. Ojo, F. Orio, H. Kahleova, G. Balercia, W.B. Grant, P.D. Rosa, A. Colao, G. Muscogiuri, The impact of vitamin D deficiency on patients ongoing kidney transplantation: focus on cardiovascular, metabolic, and endocrine outcomes. Endocrine. 50, 568–574 (2015)CrossRefPubMed
17.
D. Martins, M. Wolf, D. Pan, A. Zadshir, N. Tareen, R. Thadhani, A. Felsenfeld, B. Levine, R. Mehrotra, K. Norris, Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the third national health and nutrition examination survey. Arch. Intern. Med. 167, 1159–1165 (2007)CrossRefPubMed
18.
E. Giovannucci, Y. Liu, B.W. Hollis, E.B. Rimm, 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168, 1174–1180 (2008)CrossRefPubMed
19.
T. Skaaby, L.L.N. Husemoen, C. Pisinger, T. Jørgensen, B.H. Thuesen, M. Fenger, A. Linneberg, Vitamin D status and incident cardiovascular disease and all-cause mortality: a general population study. Endocrine. 43, 618–625 (2013)CrossRefPubMed
20.
E. Kassi, C. Adamopoulos, E.K. Basdra, A.G. Papavassiliou, Role of vitamin D in atherosclerosis. Circulation. 128, 2517–2531 (2013)CrossRef
21.
M. Bozic, Á. Álvarez, C. de Pablo, M.D. Sanchez-Niño, A. Ortiz, X. Dolcet, M. Encinas, E. Fernandez, J.M. Valdivielso, Impaired vitamin D signaling in endothelial cell Leads to an enhanced leukocyte-endothelium interplay: implications for atherosclerosis development. PLoS. ONE. 10, e0136863 (2015)CrossRefPubMed
22.
H. Dobnig, S. Pilz, H. Scharnagl, W. Renner, U. Seelhorst, B. Wellnitz, J. Kinkeldei, B.O. Boehm, G. Weihrauch, W. Maerz, Independent association of low serum 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168, 1340–1349 (2008)CrossRef
23.
X. Sun, Z.B. Cao, Y. Zhang, Y. Ishimi, I. Tabata, M. Higuchi, Association between serum 25-hydroxyvitamin D and inflammatory cytokines in healthy adults. Nutrients 6, 221–230 (2014)CrossRefPubMed
24.
J. Beilfuss, V. Berg, M. Sneve, R. Jorde, E. Kamycheva, Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cytokine. 60, 870–874 (2012)CrossRef
25.
S.J. Sokol, V. Srinivas, J.P. Crandall, M. Kim, G. Tellides, A.H. Lebastchi, Y. Yu, A.K. Gupta, M.H. Alderman, The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease. Vasc. Med. 17, 394–404 (2012)CrossRef
26.
G. Targher, L. Bertolini, R. Padovani, L. Zenari, L. Scala, M. Cigolini, G. Arcaro, Serum 25‐hydroxyvitamin D3 concentrations and carotid artery intima‐media thickness among type 2 diabetic patients. Clin. Endocrinol. 65, 593–597 (2006)CrossRef
27.
A.L. Carrelli, M.D. Walker, H. Lowe, D.J. McMahon, T. Rundek, R.L. Sacco, Vitamin D deficiency is associated with subclinical carotid atherosclerosis. The Northern Manhattan study. Stroke. 42, 2240–2245 (2011)CrossRefPubMed
28.
V. Carnevale, R. Minonne, A. De Matthaeis, M.A. Annese, P. Tabacco, P. D’Arcangelo, G. D’Amico, A. Scillitani, Carotid intima-media thickness is not associated with vitamin D and PTH levels in patients admitted to an internal medicine department. Endocrine. 47, 833–838 (2014)CrossRef
29.
M. Blondon, M. Sachs, A.N. Hoofnagle, J.H. Ix, E.D. Michos, C. Korcarz, A.D. Gepner, D.S. Siscovick, J.D. Kaufman, J.H. Stei, B. Kestenbaum, I.H. de Boer, 25-Hydroxyvitamin D and parathyroid hormone are not associated with carotid intima-media thickness or plaque in the multi-ethnic study of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 33, 2639–2645 (2013)CrossRefPubMed
30.
K.M. Gurses, L. Tokgozoglu, M.U. Yalcin, D. Kocyigit, M. Dural, H. Canpinar, H. Yorgun, M.L. Sahiner, E.B. Kaya, S. Akin, A. Gurlek, D. Guc, K. Aytemir, Markers of subclinical atherosclerosis in premenopausal women with vitamin D deficiency and effect of vitamin D replacement. Atherosclerosis. 237, 784–789 (2014)CrossRefPubMed
31.
S. Salekzamani, H. Mehralizadeh, A. Ghezel, Y. Salekzamani, M.A. Jafarabadi, A.S. Bavil, B.P. Gargari, Effect of high-dose vitamin D supplementation on cardiometabolic risk factors in subjects with metabolic syndrome: a randomized controlled double-blind clinical trial. J. Endocrinol. Invest. 39, 1303–1313 (2016)CrossRefPubMed
32.
F. Azizi, F. Hadaegh, D. Khalili, A. Esteghamati, F. Hosseinpanah, A. Delavari, B. Larijani, P. Mirmiran, A. Zabetian, Y. Mehrabi, R. Kelishadi, H. Aghajani, Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity. Arch. Iran. Med. 13, 426–428 (2010)PubMed
33.
M. Saghaei, Random allocation software for parallel group randomized trials. BMC. Med. Res. Methodol. 4, 26–31 (2004)CrossRefPubMed
34.
M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari, C.M. Gordon, D.A. Hanley, R.P. Heaney, M.H. Murad, C.M. Weaver, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930 (2011)CrossRefPubMed
35.
R.P. Heaney, Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr. Rev. 72, 48–54 (2014)CrossRefPubMed
36.
A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96, 53–58 (2011)CrossRef
37.
IPAQ Research Committee, Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ)–short and long forms. Retrieved September 17, 2008 (2005)
38.
C.L. Craig, A.L. Marshall, M. Sjostrom, A.E. Bauman, M.L. Booth, B.E. Ainsworth, M. Pratt, U. Ekelund, A. Yngve, J.F. Sallis, P. Oja, International physical activity questionnaire: 12-country reliability and validity. Med. Sci. Sports. Exerc. 195, 3508–1381 (2003)
39.
A.G. Pittas, S.S. Harris, P.C. Stark, B. Dawson-Haghes, the effects of calcium and vitamin D supplementation on blood glugose and markers of inflammation in nondiabetic adults. Diabetes. Care. 30, 980–986 (2007)CrossRefPubMed
40.
M. Kim, W. Na, C. Sohn, Correlation between vitamin D and cardiovascular disease predictors in overweight and obese Koreans. J. Clin. Biochem. Nutr. 52, 167–171 (2013)CrossRefPubMed
41.
S. Shab‐Bidar, T.R. Neyestani, A. Djazayery, M.R. Eshragian, A. Houshiarrad, A. Kalayi, N. Shariatzadeh, N. Khalaji, A. Garavi, Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes. Metab. Res. Rev. 28, 424–430 (2012)CrossRefPubMed
42.
R. Jorde, M. Sneve, P.A. Torjesen, Y. Figenschau, L.G. Gøransson, R. Omdal, No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine. 50, 175–180 (2010)CrossRefPubMed
43.
P.D. Chandler, J.B. Scott, B.F. Drake, K. Ng, J.E. Manson, N. Rifai, A.T. Chan, G.G. Bennett, B.W. Hollis, E.L. Giovanucci, K.M. Emmons, C.S. Fuch, Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial. Cancer. Prev. Res 7, 218–225 (2014)CrossRef
44.
M. Gannage-Yared, M. Azoury, I. Mansour, R. Baddoura, G. Halaby, R. Naaman, Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J. Endocrinol. Invest. 26, 748–753 (2003)CrossRefPubMed
45.
M. Rohla, T. Weiss, Metabolic syndrome, inflammation and atherothrombosis. Hämostaseologie 33, 283–294 (2013)CrossRefPubMed
46.
P.M. Ridker, N. Rifai, M.J. Stampfer, C.H. Hennekens, Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101, 1767–1772 (2000)CrossRefPubMed
47.
C. Langenberg, J. Bergstrom, C. Scheidt-Nave, J. Pfleischifter, E. Barret-Connor, Cardiovascular death and the metabolic syndrome–role of adiposity-signaling hormones and inflammatory markers. Diabetes. Care. 29, 1363–9136 (2006)CrossRefPubMed
48.
C.M. Matter, C. Handschin, RANTES (regulated on activation, normal T cell expressed and secreted), inflammation, obesity, and the metabolic syndrome. Circulation. 115, 946–948 (2007)CrossRefPubMed
49.
M.M. Assimon, P.V. Salenger, H.A. EL‐Fawal, D.L. Mason, Nutritional vitamin D supplementation in haemodialysis: a potential vascular benefit? Nephrology. 17, 237–242 (2012)CrossRefPubMed
50.
K. Kudo, S. Hasegawa, Y. Suzuki et al., 1α, 25-Dihydroxyvitamin D 3 inhibits vascular cellular adhesion molecule-1 expression and interleukin-8 production in human coronary arterial endothelial cells. J. Steroid. Biochem. Mol. Biol. 132, 290–294 (2012)CrossRefPubMed
51.
M. Kocijancic, Z. Cubranic, B. Vujicic, S. Racki, S. Dvornik, L. Zaputovic, Soluble intracellular adhesion molecule-1 and omentin-1 as potential biomarkers of subclinical atherosclerosis in hemodialysis patients. Int. Urol. Nephrol. 48, 1145–1154 (2016)CrossRefPubMed
52.
M. Aviram, M. Rosenblat, D. Gaitini, S. Nitecki, A. Hoffman, L. Dornfeld, N. Volkova, D. Presser, J. Attias, H. Liker, T. Hayek, Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin. Nutr. 23, 423–433 (2004)CrossRefPubMed
Metadata
Title
The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial
Authors
Shabnam Salekzamani
Abolhassan Shakeri Bavil
Hossein Mehralizadeh
Mohammad Asghari Jafarabadi
Aymaral Ghezel
Bahram Pourghassem Gargari
Publication date
01-07-2017
Publisher
Springer US
Published in
Endocrine / Issue 1/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1317-2

Other articles of this Issue 1/2017

Endocrine 1/2017 Go to the issue

Research Letter

Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells

Review

Androgenetic alopecia: a review

Original Article

Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals

Original Article

Effects of cigarette smoke exposure during suckling on food intake, fat mass, hormones, and biochemical profile of young and adult female rats

Endocrine Methods and Techniques

Performance of low-dose cosyntropin stimulation test handled via plastic tube

Editorial

Cabergoline for hyperprolactinemia: getting to the heart of it
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits